Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Name :
Date: 29-Jul-2022
No. of pages: 714
Inquire Before Buying

Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Drugs In Development, 2022, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.

Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 20, 51, 51, 3, 100, 30 and 1 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 11 molecules, respectively.

Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ulcerative Colitis - Overview
Ulcerative Colitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Ulcerative Colitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ulcerative Colitis - Companies Involved in Therapeutics Development
Ulcerative Colitis - Drug Profiles
Ulcerative Colitis - Dormant Projects
Ulcerative Colitis - Discontinued Products
Ulcerative Colitis - Product Development Milestones
Featured News & Press Releases
Jul 27, 2022: EC grants approval for AbbVie's Rinvoq to treat ulcerative colitis in adults
Jul 21, 2022: Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz (adalimumab-adaz) high concentration formulation (HCF)
Jul 18, 2022: Prometheus Biosciences completes enrollment of the ARTEMIS-UC cohort 1 phase 2 study in ulcerative colitis
Jul 07, 2022: Biora Therapeutics announces successful completion of second device performance study in human subjects for its targeted therapeutics platform
Jul 06, 2022: Applied Molecular Transport announces top-line phase 2 results from MARKET combination trial of oral AMT-101 in patients with moderate-to-severe ulcerative colitis
Jul 06, 2022: Applied Molecular Transport to report top-line phase 2 results from MARKET combination trial of oral AMT-101 in patients with moderate-to-severe ulcerative colitis
Jul 04, 2022: Innovent Phase II ulcerative colitis antibody trial doses first subject
Jun 20, 2022: EMA accepts Sandoz's application for high concentration of biosimilar
Jun 08, 2022: Prometheus Biosciences provides enrollment update in APOLLO-CD and ARTEMIS-UC global phase 2 Studies
May 31, 2022: Biora Therapeutics shares presentation of patient data establishing correlation between drug levels in colon and patient outcomes in ulcerative colitis
May 27, 2022: The lancet publishes results from phase 3 induction and maintenance programs evaluating Upadacitinib (RINVOQ) in ulcerative colitis
May 24, 2022: InDex Pharmaceuticals to exhibit at Digestive Disease Week
May 24, 2022: Pfizer presents ELEVATE pivotal findings demonstrating etrasimod's potentially best-in-class profile in ulcerative colitis
May 24, 2022: Fifty percent of patients with ulcerative colitis treated with Mirikizumab achieved clinical remission at one year in Lilly's pivotal phase 3 study
May 24, 2022: Alvotech clinical study results demonstrate therapeutic equivalence between biosimilar candidate AVT04 and reference product Stelara
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Ulcerative Colitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Ulcerative Colitis - Dormant Projects, 2022
Ulcerative Colitis - Discontinued Products, 2022

List of Figures
Number of Products under Development for Ulcerative Colitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
  • Global Anti Peptic Ulcer Drugs Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
    Published: 20-Sep-2022        Price: US 5600 Onwards        Pages: 111
    Report Scope This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers' production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Anti Peptic Ulcer Drugs manufacturers, distributors, end users, industry associations, governments' industry bureaus, indus......
  • Global Inflammatory Bowel Disease Drugs Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
    Published: 15-Sep-2022        Price: US 5600 Onwards        Pages: 119
    Report Scope This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers' production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Inflammatory Bowel Disease Drugs manufacturers, distributors, end users, industry associations, governments' industry burea......
  • Global Anti-Peptic Ulcer Drugs Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028
    Published: 15-Sep-2022        Price: US 5900 Onwards        Pages: 107
    Anti-peptic Ulcre drug is one of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract. Highlights Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, the global Anti-Peptic Ulcer Drugs market is projected to reach US$ 21220 million by 2028 from an estimated US$ 9979.8 million in 2022, at a CAGR of 13.4% during 2023 and 2028. Global Anti-Peptic Ulcer......
  • (Post-pandemic Era) - Global Gastrointestinal Drugs Market Segment Research Report 2022
    Published: 14-Sep-2022        Price: US 3300 Onwards        Pages: 88
    Summary The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery. 2022 is a year of continuous recovery. Global supply chain disturba......
  • Post-pandemic Era - Global Gastrointestinal Drugs Market Analysis 2022, With Top Companies, Sales, Revenue, Consumption, Price and Growth Rate
    Published: 14-Sep-2022        Price: US 4850 Onwards        Pages: 80
    Summary The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery. 2022 is a year of continuous recovery. Global supply chain disturba......
  • Global Drugs for Traveler's Diarrhea Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
    Published: 12-Sep-2022        Price: US 5600 Onwards        Pages: 106
    Report Scope This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers' production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Drugs for Traveler's Diarrhea manufacturers, distributors, end users, industry associations, governments' industry bureaus,......
  • Global Irritable Bowel Syndrome (IBS) Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028
    Published: 09-Sep-2022        Price: US 5900 Onwards        Pages: 98
    Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence ra......
  • Global Anti-Peptic Ulcer Drugs Market Research Report 2022 - Market Size, Current Insights and Development Trends
    Published: 08-Sep-2022        Price: US 3450 Onwards        Pages: 109
    The report focuses on the Anti-Peptic Ulcer Drugs market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market. M......
  • Global Lansoprazole Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
    Published: 07-Sep-2022        Price: US 5600 Onwards        Pages: 127
    Report Scope This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers' production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Lansoprazole manufacturers, distributors, end users, industry associations, governments' industry bureaus, industry publica......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs